Cover Image
市場調查報告書

腎細胞癌 (RCC):流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析

Renal cell cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365186
出版日期 內容資訊 英文 283 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腎細胞癌 (RCC):流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析 Renal cell cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 283 Pages
簡介

本報告提供腎細胞癌的已上市及臨床實驗中 (開發平台上)的治療藥相關分析,美國,市場上腎細胞癌 (RCC) 增加的要素、 PD-1 日本,及EU主要5個國家抑制劑 Opdivo的投入帶給RCC市場的影響,開發中的RCC治療藥可取得認證的時期和商業化預測,及主要首發藥的一般化帶給整體RCC市場規模的影響等相關彙整。

預測:腎細胞癌

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Afinitor (everolimus)
  • AGS-003
  • Atezolizumab
  • Avastin (bevacizumab)
  • Cometriq (cabozantinib)
  • Inlyta (axitinib)
  • Lenvima (lenvatinib)
  • Nexavar (sorafenib)
  • Opdivo (nivolumab)
  • Sutent (sunitinib)
  • Torisel (temsirolimus)
  • Votrient (pazopanib)
  • 1次調查手法

治療:腎細胞癌

  • 摘要整理
  • 1次調查手法
  • 疾病定義、診斷
  • 患者區分
  • 各國治療系統
  • 目前治療選擇
  • 處方趨勢

流行病學:腎細胞癌

  • 摘要整理
  • 疾病的背景
  • 來源、手法
  • 預測
  • 流行病學者的見解
  • 優勢和弱點

上市藥:腎細胞癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Afinitor
  • 產品簡介:Avastin
  • 產品簡介:Inlyta
  • 產品簡介:Nexavar
  • 產品簡介:Opdivo
  • 產品簡介:Sutent
  • 產品簡介:Torisel
  • 產品簡介:Votrient

開發平台:腎細胞癌

  • 摘要整理
  • 臨床實驗平台概要
  • 最近中止的藥物
  • 目標產品簡介
  • 臨床實驗設計
  • 腎細胞癌症的治療的未來
  • 產品簡介 (後期階段) :AGS-003
  • 產品簡介 (後期階段) :Cometriq
  • 產品簡介 (後期階段) :atezolizumab

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5807

Despite the approvals of several pipeline therapies, the renal cell cancer (RCC) market is expected to experience only moderate growth due to market saturation and the expiries of key brand patents.

This report addresses the following questions:

  • What factors are contributing to the increase in RCC incidence across the US, Japan, and five major EU markets?
  • What impact will the entry of PD-1 inhibitor Opdivo have on the RCC market?
  • When are pipeline therapies in development for RCC expected to gain approval and what is their commercial outlook?
  • How will genericization of key brands impact the overall value of the RCC market?
  • Which treatment settings represent attractive targets for drug developers?

TABLE OF CONTENTS

FORECAST: RENAL CELL CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Methodology and Market Definition
  • 4. Afinitor (everolimus)
  • 5. AGS-003
  • 6. Atezolizumab
  • 7. Avastin (bevacizumab)
  • 8. Cometriq (cabozantinib)
  • 9. Inlyta (axitinib)
  • 10. Lenvima (lenvatinib)
  • 11. Nexavar (sorafenib)
  • 12. Opdivo (nivolumab)
  • 13. Sutent (sunitinib)
  • 14. Torisel (temsirolimus)
  • 15. Votrient (pazopanib)
  • 16. Primary Research Methodology

REATMENT: RENAL CELL CANCER

  • 17. Executive Summary
  • 18. Primary Research Methodology
  • 19. Disease Definition and Diagnosis
  • 20. Patient Segmentation
  • 21. Country Treatment Trees
  • 22. Current Treatment Options
  • 23. Prescribing Trends

EPIDEMIOLOGY: RENAL CELL CARCINOMA

  • 24. Executive Summary
  • 25. Sources and Methodology
  • 26. Forecast
  • 27. Epidemiologist Insight
  • 28. Strengths and Limitations

MARKETED DRUGS: RENAL CELL CANCER

  • 29. Executive Summary
  • 30. Product Overview
  • 31. Product profile: Afinitor
  • 32. Product profile: Avastin
  • 33. Product profile: Inlyta
  • 34. Product profile: Nexavar
  • 35. Product profile: Opdivo
  • 36. Product profile: Sutent
  • 37. Product profile: Torisel
  • 38. Product profile: Votrient

PIPELINE: RENAL CELL CANCER

  • 39. Executive Summary
  • 40. Clinical Pipeline Overview
  • 41. Recently Discontinued Drugs
  • 42. Target Product Profile
  • 43. Clinical Trial Design
  • 44. The Future of Treatment in Renal Cell Cancer
  • 45. Product profile (late stage): AGS-003
  • 46. Product profile (late stage): Cometriq
  • 47. Product profile (late stage): atezolizumab

APPENDIX

  • 48. Appendix: Marketed Drugs: Renal Cell Cancer
  • 49. Appendix: Pipeline: Renal Cell Cancer
Back to Top